MLTI-11. IMPLANTABLE POLYMERIC BCNU AS AN ADJUNCT TO SURGERY FOR METASTATIC INTRACRANIAL DISEASE. (12th August 2019)

• Record Type: Journal Article
• Authors: Ryken, Timothy; Evans, Linton
• Is Part Of: Neuro-oncology advances. Volume 1(2019)Supplement 1
• Page Start: i16
• Page End: i16
• Publication Date: 2019-08-12
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdz014.070
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: SUMMARY: One hundred and thirty cases of craniotomy for tumor utilizing BCNU implantable chemotherapy were performed by the authors between including 23 cases for metastatic intracranial disease. The series included 12 woman and 11 men with an average age of 56.9 years. The diagnoses were as follows: non-small lung carcinoma (13), breast cancer (6), small-cell lung cancer (1), colon cancer (1), unknown primary (2). Patients undergoing resection plus implantable chemotherapy following whole brain radiotherapy (5 patients) or following stereotactic radiosurgery (5 patients) were the most common. Only patient developed possible local recurrence (3%). Complications included two cerebrospinal fluid leaks with associated complications requiring reoperations (11%) both following whole brain radiotherapy and 3 patients (17%) with thromboembolic episodes (3 deep venous thromboses, one with a pulmonary embolus and sudural hematoma). In this challenging population, local implantable chemotherapy appears relatively safe and a reasonable consideration as a surgical adjunct.